Etopor 100 Mg (Etoposide) Injection

Introduction

Etopor 100 mg (Etoposide) Injection is a premium quality anti-cancer medication manufactured by Eskayef Pharmaceuticals Ltd., one of Bangladesh’s leading pharmaceutical companies. As a trusted product supplied by Orio Pharma, this medication plays a crucial role in oncology treatment protocols, particularly for patients battling small cell lung cancer.

What is Etopor?

Etopor contains Etoposide, a semisynthetic derivative of podophyllotoxin specifically designed for the treatment of certain neoplastic diseases. This potent cytotoxic chemotherapy agent works by inhibiting cell cycle progression at a premitotic phase (late S and G2), effectively blocking microtubular assembly without interfering with nucleic acid synthesis.

Therapeutic Applications

Etopor is primarily indicated for the management of Small Cell Lung Cancer (SCLC). It is prescribed as part of combination therapy with other approved chemotherapeutic agents for first-line treatment. This strategic approach to cancer treatment has shown significant efficacy in clinical settings when administered under proper medical supervision.

Pharmacological Profile

Pharmacodynamics: Classified as a podophyllotoxin derivative, Etoposide halts cancer cell proliferation by preventing mitosis. Its selective action on the cell cycle provides targeted therapeutic effects against rapidly dividing cancer cells.

Pharmacokinetics: Upon intravenous administration, Etoposide displays a biphasic disposition pattern with:

Distribution half-life of approximately 1.5 hours
Terminal elimination half-life ranging from 4 to 11 hours
Total body clearance values between 33-48 ml/min or 16-36 ml/min/m²
Linear dose-response relationship for plasma concentration and AUC values
Mean volumes of distribution at steady state between 18-29 liters or 7-17 L/m²

Dosage Guidelines

For small cell lung cancer treatment, Etopor is typically administered at:

35 mg/m²/day for 4 days to 50 mg/m²/day for 5 days in combination with other chemotherapeutic agents
Dosage adjustments for patients with renal impairment based on creatinine clearance:
- 50 mL/min: 100% of standard dose
- 15-50 mL/min: 75% of standard dose
- <15 mL/min: Further dose reduction recommended

All administration should be conducted under the supervision of qualified oncologists or registered physicians with experience in cancer treatment.

Quality Assurance

Etopor 100 mg Injection represents the culmination of Eskayef Pharmaceuticals’ 31 years of pharmaceutical excellence. Each batch undergoes rigorous quality control processes to ensure consistency, potency, and safety. As a supplier, Orio Pharma maintains strict adherence to international standards for storage, handling, and distribution of this critical medication.

Safety Considerations

Before initiating treatment with Etopor, healthcare professionals should:

Conduct comprehensive blood tests including platelet count, hemoglobin, white blood cell count, and differential
Monitor patients regularly for myelosuppression during and after therapy
Be prepared to manage potential hypersensitivity reactions
Administer via slow intravenous infusion (30-60 minutes) to minimize the risk of hypotension
Exercise caution in patients with low serum albumin levels due to increased risk of toxicities

Potential Interactions and Side Effects

Etopor may interact with high-dose cyclosporine A, potentially increasing Etoposide exposure. Common side effects include:

Hematologic effects (myelosuppression, neutropenia)
Gastrointestinal symptoms (nausea, vomiting, mucositis)
Hypotension during administration
Allergic reactions in some patients
Reversible alopecia

Storage Requirements

For maximum efficacy and stability, Etopor must be stored under refrigeration at 2°-8°C. The product remains stable for 24 months when properly refrigerated. Healthcare facilities should follow proper handling and disposal procedures for anticancer drugs and protect the medication from light exposure.

Global Availability

As a dedicated supplier of oncology medications, Orio Pharma ensures worldwide delivery of Etopor within 3 to 7 working days. This commitment to rapid delivery recognizes the time-sensitive nature of cancer treatment and the importance of uninterrupted therapy protocols.

Expert Support

Orio Pharma’s team of specialists is available to provide comprehensive information about Etopor, including guidance on proper handling, storage, and administration. Healthcare professionals can rely on this expertise to optimize treatment outcomes for their patients.

Manufacturer Information

Eskayef Pharmaceuticals Limited began its journey in 1990 when Transcom Group acquired the Bangladesh operation of SK&F, USA. With over three decades of experience, Eskayef has established itself as a premier pharmaceutical manufacturer, delivering world-class medicines both domestically and internationally.

For more information about Etopor 100 mg (Etoposide) Injection or to place an order, visit www.oriopharma.com or contact our dedicated customer service team today.